Published in Ann Oncol on January 19, 2009
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol (2012) 1.69
An update on chemotherapy of colorectal liver metastases. World J Gastroenterol (2012) 1.05
Treatment of colorectal liver metastases. World J Surg Oncol (2011) 1.04
A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis (2012) 1.02
Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol (2014) 0.97
Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol (2014) 0.97
Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol (2011) 0.95
Predictors of long-term survival in patients with colorectal liver metastases: a single center study and review of the literature. Int J Colorectal Dis (2011) 0.93
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol (2011) 0.92
Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med (2013) 0.91
Neoadjuvant chemotherapy affects staging of colorectal liver metastasis--a comparison of PET, CT and intraoperative ultrasound. Int J Colorectal Dis (2010) 0.90
Liver resection for colorectal cancer metastases. Curr Oncol (2013) 0.89
B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One (2014) 0.88
Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol (2010) 0.87
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res (2013) 0.87
The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer. Oncotarget (2015) 0.86
Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol (2013) 0.85
Prognostic significance of the number of tumors and aggressive surgical approach in colorectal cancer hepatic metastasis. World J Surg Oncol (2014) 0.85
Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer (2014) 0.84
The association between preoperative chemotherapy and the prevalence of hepatic steatosis in hepatectomy for metastatic colorectal cancer. Arq Bras Cir Dig (2014) 0.84
Variation in hospital treatment patterns for metastatic colorectal cancer. Cancer (2015) 0.83
Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. PLoS One (2014) 0.83
The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg Today (2015) 0.83
Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford) (2012) 0.83
Role of quantification of hepatic steatosis and future remnant volume in predicting hepatic dysfunction and complications after liver resection for colorectal metastases: a pilot study. HPB (Oxford) (2012) 0.82
Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther (2015) 0.82
Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades. BMC Cancer (2014) 0.82
Non-invasive diagnosis of focal liver lesions: an individualized approach. Cancer Imaging (2012) 0.82
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer (2012) 0.81
Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol (2009) 0.81
Current state of surgical treatment of liver metastases from colorectal cancer. World J Gastrointest Surg (2011) 0.80
Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. Int J Clin Oncol (2011) 0.79
Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer (2016) 0.79
Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D (2011) 0.79
Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases. Am J Cancer Res (2015) 0.79
Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases. J Gastrointest Oncol (2014) 0.78
Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol (2013) 0.78
Surgical Referral for Colorectal Liver Metastases: A Population-Based Survey. Ann Surg Oncol (2015) 0.78
Role of surgery in colorectal liver metastases: too early or too late? World J Gastroenterol (2010) 0.78
Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases. Eur Radiol (2015) 0.78
Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis (2017) 0.77
Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer (2016) 0.77
Efficacy of laparoscopic liver resection in colorectal liver metastases and the influence of preoperative chemotherapy. World J Surg Oncol (2014) 0.77
Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol (2010) 0.77
Impact of totally laparoscopic combined management of colorectal cancer with synchronous hepatic metastases on severity of complications: a propensity-score-based analysis. Surg Endosc (2016) 0.77
Feasibility of the liver-first approach for patients with initially unresectable and not optimally resectable synchronous colorectal liver metastases. Surg Today (2015) 0.76
Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway. Cancer Microenviron (2014) 0.76
Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases. World J Gastrointest Oncol (2011) 0.76
Simultaneous resection for colorectal cancer and synchronous liver metastases. Surg Today (2015) 0.76
Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey. HPB (Oxford) (2014) 0.76
The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Ther Adv Med Oncol (2010) 0.75
A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer. Chin J Cancer Res (2016) 0.75
Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clin Exp Metastasis (2012) 0.75
Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World J Gastrointest Oncol (2014) 0.75
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol (2016) 0.75
Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev (2012) 0.75
Missing metastases as a model to challenge current therapeutic algorithms in colorectal liver metastases. World J Gastroenterol (2016) 0.75
The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis. Oncotarget (2016) 0.75
Major surgery in patients with metastatic colorectal cancer in Western europe. J Gastrointest Cancer (2012) 0.75
Clinical outcome of node-negative oligometastatic non-small cell lung cancer. Thorac Cancer (2016) 0.75
Resectability of initially unresectable liver metastases from colorectal cancer should not be the primary end point of clinical trials. Gastrointest Cancer Res (2009) 0.75
Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer? Ann Transl Med (2013) 0.75
Conditional survival in advanced colorectal cancer and surgery. J Surg Res (2015) 0.75
Efficacy of surgical treatment using microwave coagulo-necrotic therapy for unresectable multiple colorectal liver metastases. Onco Targets Ther (2016) 0.75
Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. PLoS One (2017) 0.75
Laparoscopic Approach for Primary Colorectal Cancer Improves Outcome of Patients Undergoing Combined Open Hepatic Resection for Liver Metastases. World J Surg (2015) 0.75
The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget (2017) 0.75
Oligometastatic Disease in Colorectal Cancer - How to Proceed? Visc Med (2017) 0.75
Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy. Onco Targets Ther (2017) 0.75
Centralization of Liver Cancer Surgery and Impact on Multidisciplinary Teams Working on Stage IV Colorectal Cancer. Oncol Rev (2017) 0.75
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med (2001) 13.75
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med (1997) 9.99
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (2007) 5.68
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol (1998) 3.79
Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ (1995) 3.30
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol (2001) 3.21
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg (2010) 3.03
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol (2002) 2.87
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol (2005) 2.84
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol (2000) 2.77
Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer (2003) 2.64
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol (2002) 2.60
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer (2006) 2.51
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 2.10
Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum (1998) 2.09
Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol (2000) 2.09
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol (1998) 2.05
Sunlight and non-Hodgkin's lymphoma: a population-based cohort study in Sweden. Int J Cancer (1999) 1.97
Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol (1994) 1.96
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol (2004) 1.95
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg (1990) 1.93
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer (2001) 1.92
Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy. Br J Surg (2008) 1.87
Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum (1993) 1.87
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol (1990) 1.86
Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg (2007) 1.85
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol (1998) 1.80
Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain (2009) 1.77
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol (2009) 1.77
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol (1996) 1.76
Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut (2005) 1.75
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst (1995) 1.74
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.72
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer (2004) 1.70
Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver (1998) 1.67
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.67
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer (2002) 1.66
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg (1995) 1.64
Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res (1999) 1.63
A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol (2001) 1.61
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol (2002) 1.61
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer (2009) 1.60
Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Br J Surg (2011) 1.60
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg (2012) 1.60
Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol (1996) 1.59
Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis (1981) 1.58
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer (2005) 1.58
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg (2013) 1.56
Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol (2008) 1.56
Modelling the polypeptide backbone with 'spare parts' from known protein structures. Protein Eng (1989) 1.54
Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying. Gut (1998) 1.54
Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer. Br J Surg (2006) 1.54
Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res (2003) 1.54
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol (2003) 1.52
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer (2004) 1.52
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol (2004) 1.51
Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum (1990) 1.50
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol (2001) 1.46
Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg (2005) 1.46
Relationship between age and survival in cancer of the colon and rectum with special reference to patients less than 40 years of age. Br J Surg (1990) 1.45
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol (1998) 1.45
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy (2012) 1.44